An update in the New England Journal of Medicine has shown that transcatheter arterialization of the deep veins (TADV) using ...
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company ...
Surmodics (Nasdaq:SRDX) announced results from a sex-specific analysis of real-world patients in a study of its Pounce ...
PARIS & SAN JOSE, Calif.--(BUSINESS WIRE)--LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of ...
Transcatheter arterialization of the deep veins in patients with chronic limb-threatening ischemia appeared safe and led to limb salvage and wound healing in most cases, the PROMISE II study showed.
MedPage Today on MSN
Esprit Scaffold Crosses Durability Hurdle in Below the Knee PAD
LIFE-BTK trial was designed as a superiority trial. The investigators randomly assigned 261 people 2:1 to Esprit or PTA.
Angiodynamics, Inc. (($ANGO)) announced an update on their ongoing clinical study. Study Overview: Angiodynamics, Inc. is conducting a clinical ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a novel bioresorbable scaffold for the treatment of chronic limb-threatening ischemia. The ...
A study documents poor outcomes among hospitalized patients with kidney failure and critical limb ischemia who did not receive dialysis. Critical limb ischemia is common among patients with end-stage ...
Stempeutics partners with Japan's Medinet to license Stempeucel for treating chronic limb threatening ischemia, marking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback